Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News
  • Published:

Amgen's angiopoietin blocker fails in ovarian cancer

Nature Biotechnology volume 33, pages 5–6 (2015)Cite this article

Subjects

Access through your institution
Buy or subscribe

In the first phase 3 trial, called TRINOVA-1, Amgen's trebananib had a positive effect on PFS. Individuals on a combination of the drug plus Taxol (paclitaxel) had a median PFS of 7.2 months versus 5.4 months for those in the control group. But median overall survival at 19.3 months versus 18.3 months for patients in the control group was not statistically different.

TRINOVA-2, which tested trebananib plus pegylated liposomal doxorubicin in 223 patients with recurrent, partially platinum-sensitive ovarian cancer, has yet to report overall survival data, but these are unlikely to be favorable given the lack of an effect on PFS, which Amgen disclosed during a recent investor presentation. “Part of the challenge—and you see it in the topline results from the TRINOVA-1 study—is patients are living a long time after they progress on their therapy,” says David Hyman, a medical oncologist at Memorial Sloan Kettering Cancer Center, in New York. That makes overall survival a high hurdle for new drugs to clear.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

  1. Dublin

    Cormac Sheridan

Authors
  1. Cormac Sheridan
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sheridan, C. Amgen's angiopoietin blocker fails in ovarian cancer. Nat Biotechnol 33, 5–6 (2015). https://doi.org/10.1038/nbt0115-5

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nbt0115-5

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing